Intraperitoneal Meropenem for Polymicrobial Peritoneal Dialysis-Related Peritonitis
| Autor: | Lily Jakulj, Anthe Zandvliet, Eric Franssen, Caroline W.H. de Fijter, Fariba Amiri |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Peritonitis 030226 pharmacology & pharmacy Gastroenterology Meropenem Peritoneal dialysis 03 medical and health sciences 0302 clinical medicine Short Reports Peritoneal Dialysis Continuous Ambulatory Pharmacokinetics Fixed time Internal medicine polycyclic compounds medicine Humans Infusions Parenteral Aged 80 and over business.industry General Medicine biochemical phenomena metabolism and nutrition bacterial infections and mycoses medicine.disease Drug Resistance Multiple Anti-Bacterial Agents Treatment Outcome Drug concentration Nephrology 030220 oncology & carcinogenesis bacteria Kidney Failure Chronic Female Thienamycins Patient Safety business Follow-Up Studies medicine.drug |
| Zdroj: | Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 36:572-573 |
| ISSN: | 1718-4304 0896-8608 |
| DOI: | 10.3747/pdi.2016.00023 |
| Popis: | With the current rise in multiresistant gram-negative bacteria, carbapenems are more frequently used. Surprisingly, limited data exist on the pharmacokinetics of meropenem in peritoneal dialysis (PD)-related peritonitis. We report on the pharmacokinetics of repeated intraperitoneal (IP) meropenem during 21 days as treatment for polymicrobial multiresistent PD-related peritonitis. Our current report supports daily doses of 125 mg/L intraperitoneal meropenem in all bags as an effective and safe modality in the treatment of PD-associated peritonitis with multiresistant microorganisms. No signs of over- or underdosing were found based on serial drug concentration measurements at fixed time points up to 21 days. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|